| Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes BL Scott, MC Pasquini, BR Logan, J Wu, SM Devine, DL Porter, ... Journal of Clinical Oncology 35 (11), 1154-1161, 2017 | 628 | 2017 |
| Current use of and trends in hematopoietic cell transplantation in the United States A D'Souza, C Fretham, SJ Lee, M Arora, J Brunner, S Chhabra, S Devine, ... Biology of Blood and Marrow Transplantation 26 (8), e177-e182, 2020 | 456 | 2020 |
| Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial NN Shah, BD Johnson, D Schneider, F Zhu, A Szabo, CA Keever-Taylor, ... Nature medicine 26 (10), 1569-1575, 2020 | 386 | 2020 |
| Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial PF Caimi, W Ai, JP Alderuccio, KM Ardeshna, M Hamadani, B Hess, ... The Lancet Oncology 22 (6), 790-800, 2021 | 372 | 2021 |
| Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease CS Hourigan, LW Dillon, G Gui, BR Logan, M Fei, J Ghannam, Y Li, ... Journal of Clinical Oncology 38 (12), 1273-1283, 2020 | 353 | 2020 |
| Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an … SK Kumar, JG Berdeja, R Niesvizky, S Lonial, JP Laubach, M Hamadani, ... The Lancet Oncology 15 (13), 1503-1512, 2014 | 332 | 2014 |
| Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors AS Kanate, A Mussetti, MA Kharfan-Dabaja, KW Ahn, A DiGilio, ... Blood, The Journal of the American Society of Hematology 127 (7), 938-947, 2016 | 296 | 2016 |
| Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-cell–replete haploidentical donor transplantation using post-transplant … A Bashey, MJ Zhang, SR McCurdy, A St. Martin, T Argall, C Anasetti, ... Journal of Clinical Oncology 35 (26), 3002-3009, 2017 | 286 | 2017 |
| PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD BM Haverkos, D Abbott, M Hamadani, P Armand, ME Flowers, ... Blood, The Journal of the American Society of Hematology 130 (2), 221-228, 2017 | 282 | 2017 |
| Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant … N Ghosh, R Karmali, V Rocha, KW Ahn, A DiGilio, PN Hari, V Bachanova, ... Journal of Clinical Oncology 34 (26), 3141-3149, 2016 | 251 | 2016 |
| Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy AS Kanate, NS Majhail, BN Savani, C Bredeson, RE Champlin, ... Biology of Blood and Marrow Transplantation 26 (7), 1247-1256, 2020 | 213 | 2020 |
| Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI EA Copelan, BK Hamilton, B Avalos, KW Ahn, BJ Bolwell, X Zhu, M Aljurf, ... Blood, The Journal of the American Society of Hematology 122 (24), 3863-3870, 2013 | 194 | 2013 |
| Autologous transplantation for newly diagnosed multiple myeloma in the era of novel agent induction: a systematic review and meta-analysis B Dhakal, A Szabo, S Chhabra, M Hamadani, A D’Souza, SZ Usmani, ... JAMA oncology 4 (3), 343-350, 2018 | 176 | 2018 |
| Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American … T Jain, M Bar, AJ Kansagra, EA Chong, SK Hashmi, SS Neelapu, M Byrne, ... Biology of Blood and Marrow Transplantation 25 (12), 2305-2321, 2019 | 174 | 2019 |
| Clinical practice recommendations on indication and timing of hematopoietic cell transplantation in mature T cell and NK/T cell lymphomas: an international collaborative effort … MA Kharfan-Dabaja, A Kumar, E Ayala, M Hamadani, P Reimer, ... Biology of Blood and Marrow Transplantation 23 (11), 1826-1838, 2017 | 173 | 2017 |
| Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis J Bolaños-Meade, M Hamadani, J Wu, MM Al Malki, MJ Martens, ... New England Journal of Medicine 388 (25), 2338-2348, 2023 | 172 | 2023 |
| Secondary solid cancer screening following hematopoietic cell transplantation Y Inamoto, NN Shah, BN Savani, BE Shaw, AA Abraham, IA Ahmed, ... Bone marrow transplantation 50 (8), 1013-1023, 2015 | 171 | 2015 |
| Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing … TS Fenske, MJ Zhang, J Carreras, E Ayala, LJ Burns, A Cashen, LJ Costa, ... Journal of clinical oncology 32 (4), 273-281, 2014 | 168 | 2014 |
| Early failure of frontline rituximab-containing chemo-immunotherapy in diffuse large B cell lymphoma does not predict futility of autologous hematopoietic cell transplantation M Hamadani, PN Hari, Y Zhang, J Carreras, G Akpek, MD Aljurf, E Ayala, ... Biology of Blood and Marrow Transplantation 20 (11), 1729-1736, 2014 | 165 | 2014 |
| Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant … V Gupta, AK Malone, PN Hari, KW Ahn, ZH Hu, RP Gale, KK Ballen, ... Biology of Blood and Marrow Transplantation 20 (1), 89-97, 2014 | 162 | 2014 |
Anita D'Souza MDMedical College of WisconsinVerified email at mcw.edu